
Construction begins on Boston's new $100 million Holocaust museum
When general contractor Lee Kennedy Co. completes the project in late 2026, the Holocaust Museum Boston will stretch across six floors of a 33,000-square-foot building at 125 Tremont St., facing Boston Common and the State House. Kipnis, a former dental hygienist, now leads the Holocaust Legacy Foundation, a nonprofit she formed in 2018 with Ruderman to keep the stories and lessons from the Holocaust alive for new generations.
Their foundation bought a three-story building on that site for $11.5 million in 2022, using money that Ruderman and Kipnis contributed. Their initial plans called for retrofitting the structure, but then they decided to build something new, and twice the size, to fulfill their ambitious vision. They expect construction costs will total around $100 million, and say they've already raised around two-thirds of it. A supplemental budget under consideration at the State House could provide up to $10 million in state funds as well.
Advertisement
It all started with a trip they took in 2018 to Auschwitz with Holocaust survivor and friend David Schaecter, who told them: You've seen Auschwitz, so now what are you going to do? The foundation they created was initially intended to fund fellowships for teens to learn about the Holocaust. The COVID-19 pandemic paused that plan, so Kipnis and Ruderman came up with a more ambitious one, building a museum. Schaecter helped create a Holocaust memorial in Miami Beach, Fla., near where he lives. But Ruderman, owner of the Value Store It chain of self-storage sites, says his friend and former business associate is 'kind of shocked we took it to this level.'
Advertisement
Kipnis said the Boston site is ideal, not just because of all the people who walk by it every day, but also for its proximity to other themed landmarks, such as the Freedom Trail and the Embrace statue on the Common.
'Think about what all these things represent: It's resistance, it's courage,' Kipnis said.
When it opens, the museum will feature a donated Nazi-era rail car, personal artifacts from the Holocaust, as well as an interactive holographic exhibit featuring interviews with Schaecter. (The 30-foot-long rail car is being donated by Sonia Breslow of Arizona, the daughter of a Holocaust survivor.)
'This is not a Jewish museum, this is a museum for everyone,' Ruderman said. 'We're using the Jewish people as an example of what happens when democracy breaks down.'
Kipnis added: 'This museum will ensure their stories are told, and the lessons of the Holocaust are not forgotten.'
Advertisement
This is an installment of our weekly Bold Types column about the movers and shakers on Boston's business scene.
Jon Chesto can be reached at
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Axios
23 minutes ago
- Axios
Chicago transit budget crisis deepens as funding stalls in Springfield
After months of grave warnings by Chicago-area transit leaders, unions and commuters, the Illinois General Assembly passed a $55 billion budget without the funding and reform agencies hoped for. Why it matters: Leaders warned they need $1.5 billion to prevent service cuts and layoffs at CTA, Metra and Pace. State of play: The Senate approved a proposal Saturday that would create a new governing body for Chicago-area transit as well as revenue from a fee on Uber Eats, Amazon, and other online food and retail deliveries. Yes, but: The House failed to take it up. Catch up quick: The Regional Transit Authority (RTA), which oversees CTA, Metra commuter rail and Pace suburban bus service, launched the "Save Transit Now" campaign in April, which encouraged riders to tell state legislators to include transit funding in the 2026 budget. A $770 million budget shortfall resulted from the expiration of COVID-era federal funding and a decline in ridership to pre-pandemic levels. Friction point: Lawmakers repeated throughout the session that state funding would not come without reform, saying a streamlined governing body was needed as well as better efforts to address safety on trains and buses. Additionally, the perennial issue in budget negotiations was at play, as downstate lawmakers pushed back against any legislation that would tax their districts to fund services their constituents don't use. Zoom out: The bill that passed the Senate included a new agency called Northern Illinois Transit Authority (NITA), which would replace RTA to oversee CTA, Metra, and Pace. NITA would have the authority to set and coordinate fares, allowing riders to use one fare card for all services. It also includes plans for a task force of officers from the Cook County Sheriff's Office, and Chicago, Metra and Illinois State Police dedicated to crime mitigation on transit. What they're saying: RTA spokesperson Tina Fassett Smith said in a statement that, "Balancing regional interests is challenging, but we are ready to continue our work to achieve consensus and deliver a solution." "In the coming weeks, the RTA will work with the Service Boards on a regional budget that by law must only include funding we are confident the system will receive in 2026," Smith said. Saturday's inaction "jeopardizes Illinois transit systems with expected cuts, massive layoffs, and service disruptions," Illinois AFL-CIO President Tim Drea said in a statement, adding that riders and workers are now "left concerned about the future of our communities." Between the lines: Pritzker said Sunday funding transit quickly is imperative, but took a shot at RTA's $750,000 "Save Transit Now" campaign. "I also would say that they'd have more money in their coffers if they hadn't spent money advertising here in Springfield to try to convince people of something that they really should be leaving to the legislators to decide," the governor said at a press conference. What's next: Pritzker said transit funding remains a priority and expects lawmakers to revisit the issue in the coming months.
Yahoo
3 hours ago
- Yahoo
‘Lilo & Stitch': All The Box Office Records Broken
Disney's Lilo & Stitch has teed up this summer's box office to arguably become the best one since Covid with a projected $4.2 billion in the U.S. and Canada after breaking a slew of records over its opening Memorial Day weekend frame. The $100 million live-action feature take of the 2002 animated classic broke even thanks to its rich merchandise and ancillaries, with a breakeven point of $205 million worldwide per film finance analysts. More from Deadline 'Lilo & Stitch' Live Action Cast Guide: Who Plays Who? Live-Action 'Lilo & Stitch' Soundtrack: All The Songs You'll Hear 'Lilo & Stitch' Swings To Best Tuesday In May For PG Movie At $15M+; Disney Pic Crossing $200M Today - Box Office Let's take a look at all the box office records it has broken. Biggest 4-Day Memorial Day Weekend Box Office Ever, at $182.6M, unseating 2022's Top Gun: Maverick ($160.5M). Biggest Opening Ever For a Rideback Production, with a 3-day of $146M, besting It: Chapter One's $123.4M. Biggest Opening Ever for Director Dean Fleischer Camp. His previous opening was A24's Marcel the Shell With Shoes On at $159,000 from six theaters. Biggest 3-day Opening for a PG Movie In May, ahead of 2007's Shrek the Third ($121.6M). Biggest Tuesday In May for a PG Movie at $15.2M, ahead of Disney's Aladdin ($12M) in 2019. Biggest 4-day Memorial Day Weekend at Domestic Box Office For All Films at $329.8M, per Comscore, unseating Memorial Day Weekend 2013 which minted $314.3M after Fast & Furious 6 led with a $117M opening. OTHER NOTABLE ACHIEVEMENTS Second Biggest 4-Day Holiday Opening, after Black Panther's $242.1M in its debut over the 2018 Presidents Day weekend. Second Biggest Opening YTD after Warner Bros/Legendary's A Minecraft Movie ($162.7M). Third Biggest Opening for a Disney Live-Action Feature Adaptation of a Classic Toon, behind 2019's The Lion King ($191.7M) and 2017's Beauty and the Beast ($174.7M). Fifth Biggest Monday of All-Time at $36.5M, after Black Panther ($40.15M, February 19, 2018), Star Wars: The Force Awakens ($40.10M, December 21, 2015), Spider-Man: No Way Home ($37.1M, December 20, 2021) and Avengers: Endgame ($36.8M, April 29, 2019). AMC and Odeon's Most Attended 5 Days YTD at 7 million, combined both stateside and abroad. AMC is reporting, but not providing numbers, that it was the chain's most-attended Memorial Day weekend in the U.S. since 2013. It was also the No. 1 exhibitor's third-best 5-day (Thursday-Monday) in more than decade when it came to overall revenue (admissions plus concessions). Regal Cinemas' Most Attended Memorial Day Weekend Ever with more than 3 million moviegoers at the nation's No. 2 chain. It also served 103 million buckets of popcorn. Highest Opening YTD for an MPA Movie at the International Box Office YTD at $158.7M. Highest Disney Live-Action Opening of All Time Across Latin America. Mexico was the No. 1 market with $27M, Brazil was third with $12.2M. NOTABLE ACHIEVEMENTS Third highest Disney Live-Action Worldwide Opening at $342M, behind The Lion King ($433M) and Beauty and the Beast ($357). Disney First Studio To Cross $2 Billion YTD, ahead of all other studios at the global box office. Best of Deadline 2025-26 Awards Season Calendar: Dates For Tonys, Emmys, Oscars & More Everything We Know About Netflix's 'The Thursday Murder Club' So Far 2025 TV Series Renewals: Photo Gallery
Yahoo
3 hours ago
- Yahoo
Terrible News for Pfizer Stock Investors
While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results. However, recent regulatory changes in the U.S. should make this franchise somewhat less lucrative. Even so, Pfizer's hopes of a comeback lie elsewhere, especially in its improving oncology unit. 10 stocks we like better than Pfizer › The past three years have been challenging for Pfizer (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022. Although Pfizer has made some efforts to turn things around, they have been insufficient. And recent regulatory developments in the U.S. somewhat complicate things for the drugmaker. Here's what investors need to know. Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks to its work in this area, once the pandemic started receding, sales from Comirnaty, its COVID-19 vaccine, and Paxlovid, its therapy for the disease, started dropping off a cliff. However, Pfizer's coronavirus franchise has remained critical to its overall financial results. In 2024, the company's combined revenue from Paxlovid and Comirnaty was $11.1 billion. Pfizer's total top line came in at $63.6 billion, increasing 7% compared to the year-ago period. When excluding contributions from its coronavirus products, Pfizer's revenue grew more quickly -- by 12% year over year. The company's sales were down compared to 2023 but still accounted for about 17.5% of its top line. That's a meaningful amount. Pfizer would be in a lot more trouble without Paxlovid and Comirnaty. Here's the problem: Recent regulatory changes in the U.S. will make it more challenging for Pfizer to consistently generate solid revenue from Comirnaty. The U.S. Food and Drug Administration (FDA) has decided that instead of recommending COVID-19 vaccines for healthy adults and children above a certain age, it will do so only for seniors aged 65 and older and those with certain medical conditions that put them at risk of severe disease outcomes. The agency is requiring additional clinical trials before it can recommend annual booster shots for healthy adults. Healthy children and pregnant women are also no longer on the list of those who should take the vaccine. These changes will take effect in the fall, peak vaccination season for COVID-19. In other words, the U.S. coronavirus vaccine market just became smaller. What does this mean for investors? Pfizer's coronavirus franchise might weaken somewhat as a result of these changes, but perhaps not significantly. The FDA's guidance is largely irrelevant to Paxlovid. We could even speculate that lower vaccination rates may actually lead to higher infection rates and more prescriptions for the medicine. Although Comirnaty's U.S. sales will be affected, the company reported just $2.004 billion in revenue from the U.S. coronavirus vaccine market last year, which accounts for about 37% of the total revenue Comirnaty generated. The U.S. market is the single most important for Pfizer. Overall, these new developments won't have a significant impact on its financial results. Even so, Pfizer continues to encounter headwinds, and this is yet another one. It might not be a big deal in a vacuum, but given Pfizer's trajectory since 2022, it's not exactly what investors want to see. Truth be told: Pfizer needs every single dollar it can collect in sales. Even slightly lower revenue than it expects from any medicine or vaccine is terrible news for a company whose midpoint revenue guidance of $62.5 billion for the year implies a slight decrease compared to 2024. In light of all this, it's fair for investors to look at the company's performance over the past few years and wonder whether it can bounce back. If it does, it will unlikely be because of its work in the coronavirus vaccine market. Pfizer has made significant strides in recent years to strengthen its pipeline. One of its latest moves was to expand its already robust portfolio of oncology candidates with the licensing of a promising cancer medicine, called SSGJ-707, originally developed by China-based 3S Bio. Pfizer dished out an upfront payment of $1.25 billion for this mid-stage asset, with potential milestone payments of up to $4.8 billion on top of royalties. Pfizer's comeback story will almost certainly include at least one, if not several, significant regulatory wins in oncology. Given its massive pipeline in the field and vast experience in developing drugs in this area, the drugmaker should be well-positioned to achieve this goal. Pfizer is working on numerous therapies in other fields as well and is enhancing its business in various ways. The healthcare company has decreased expenses and costs and plans to continue doing so until 2027. In my view, thanks to its equally massive success in the coronavirus market earlier this decade, we have yet to see the results of the massive investments Pfizer made in its pipeline, It's not time to give up on the stock just yet, even with the recent regulatory changes in the U.S. Pfizer could still generate excellent returns for patient investors. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Terrible News for Pfizer Stock Investors was originally published by The Motley Fool Sign in to access your portfolio